Apr 18,2023

Dr. Fatima Cody Stanford joins Vida Health’s Clinical Advisory Council

Virtual cardiometabolic care leader Vida Health announced the addition of renowned obesity care expert Fatima Cody Stanford MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS to its clinical advisory council. Dr. Stanford is a nationally recognized obesity medicine physician, scientist, educator, and policy maker. She currently serves as an Associate Professor of Medicine and Pediatrics at Harvard Medical School, as an Obesity Medicine Physician at Massachusetts General Hospital and the MGH Weight Center, and as a member of President Biden’s USDA 2025 Dietary Guidelines Advisory Committee.

View Analyst & Ambassador Comments
Go to original news
Jul 10,2023

Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes

Better Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) authorized AspyreRx™ (formerly BT-001), a prescription-only digital therapeutic (PDT) treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes (T2D). AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices. AspyreRx is expected to launch commercially in Q4 2023?. Frank Karbe, Chief Executive Officer at Better Therapeutics commented “This De Novo authorization also provides a foundation for potential future growth opportunities. Given cardiometabolic diseases share common underlying factors that contribute to their development and progression, we intend to expand our PDT platform to multiple related conditions in the future.”

REGULATORY FDA

#dtx

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 12,2023

Omada Health Earns Three-Year NCQA Population Health Program Accreditation

After being the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s (NCQA) Population Health Program (PHP) Accreditation in 2021, Omada Health has been awarded this accreditation for an additional three years. Omada for Diabetes and Diabetes+Hypertension programs will be accredited through 2026. NCQA is a private, non-profit organization dedicated to improving health care quality. Their accreditation standards for Population Health Management Programs are developed with input from various stakeholders and resources, including health plans, population health management industry leaders and organizations, an expert panel and standing committees.

PRODUCT

#virtual care

#dtx

View Analyst & Ambassador Comments
Go to original news
Jul 10,2023

Diabetes Care Devices Market Prediction by 2032 Growing at 8.06% CAGR, The Brainy Insights Says

The diabetes care devices market will grow to USD 11.72 billion in 2022 and reach USD 25.45 billion by 2032, according to the research publisher. North America is expected to have the largest market share in diabetes care devices because of the factors including easy availability of diabetes devices, an increasing number of initiatives by the government & favourable reimbursement policies, unhealthy eating habits, and increased awareness about diabetes management.

View Analyst & Ambassador Comments
Go to original news
Jul 12,2023

Smart Insulin Pens Market to Garner $191.26 Million by 2032

The smart insulin pens market will grow from USD 67.91 Million in 2022 to USD 191.26 Million by 2032, according to the research publisher. Europe is expected to have the most major smart insulin pens market share during the forecast period. The distribution channel segment is divided into hospital pharmacy, online pharmacy, and retail pharmacy. The online pharmacy segment is expected to augment the market during the forecast period.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jul 06,2023 TOP STORY

Medicare now covers new Medtronic MiniMed 780G automated insulin pump

Medtronic announced today that Medicare now covers its new MiniMed 780G system with the Guardian 4 sensor. Coverage for the recently FDA-approved automated insulin delivery system extends to all eligible Medicare and Medicare Advantage beneficiaries. The company plans to start shipments to eligible recipients with type 1 diabetes over the next few weeks. The MiniMed 780G system features SmartGuard technology and Meal Detection Technology, providing automatic adjustments to sugar levels without fingersticks and optimizing insulin delivery. Medtronic presented positive data on the system's Meal Time Technology at the American Diabetes Association Scientific Sessions.

PRODUCT

#cgm

#insulin pump

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Jul 06,2023

Insulin delivery tech developer Modular Medical names former Insulet CEO to board

Modular Medical has appointed industry veteran Duane DeSisto, former CEO of Insulet, to its board of directors. Modular Medical aims to launch the next generation of insulin patch pump, focusing on providing ease of use and affordability. The San Diego-based company is a development-stage insulin delivery technology company.

View Analyst & Ambassador Comments
Go to original news
Jul 06,2023

France $3.39 Bn Diabetes Markets to 2028: Insulin Pump, CGM, Self-Monitoring Blood Device and Company Analysis

The France Diabetes Market is projected to reach $3.39 billion by 2028, growing at a CAGR of 2.75% from 2023 to 2028, according to the publisher. The market is driven by the increasing prevalence of diabetes, growing obese population, and unhealthy lifestyles. Key segments include self-monitoring blood glucose (SMBG) devices, continuous glucose monitoring (CGM) systems, and insulin pumps.

View Analyst & Ambassador Comments
Go to original news
Jul 06,2023

Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time

DexCom will release its Q2 2023 financial results on July 27, 2023, and hold a conference call at 4:30 p.m. Eastern Time on the same day to discuss the performance. The webcast will be available on the Dexcom investor relations website.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 06,2023 TOP STORY

Dario Announces New Full Suite Employer Contract

DarioHealth Corp. has announced a new employer contract to provide its full suite of integrated solutions to an educational organization in the Midwest. The new account is scheduled to launch in the second half of 2023. DarioHealth stated that. ''The contract represents continued demand for integrated multi-chronic solutions in the employer market and the increasing willingness of employers to launch solutions outside of the traditional benefits lifecycle as the growing costs of chronic condition management put pressure on benefits professionals.''

PRODUCT

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES